A Phase 1, Open-Label Study to Investigate Drug-Drug Interaction (DDI) Potential of Nipocalimab With Coadministration of Etanercept or Hydroxychloroquine in Healthy Participants
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Etanercept (Primary) ; Hydroxychloroquine (Primary) ; Nipocalimab (Primary)
- Indications Autoimmune haemolytic anaemia; Haemolytic disease of newborn; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Jul 2022 Status changed from recruiting to completed.
- 17 Jun 2022 Results (n=40) of safety analysis presented at the 27th Congress of the European Haematology Association
- 16 Feb 2022 Planned End Date changed from 27 Dec 2021 to 18 Apr 2022.